These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15750398)

  • 1. Biphasic decline of CD4 cell count during scheduled treatment interruptions.
    Fagard C; Bandelier CY; Ananworanich J; Le Braz M; Günthard H; Perneger T; García F; Hirschel B;
    AIDS; 2005 Mar; 19(4):439-41. PubMed ID: 15750398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structured treatment interruptions in HIV/AIDS therapy.
    Lisziewicz J; Lori F
    Microbes Infect; 2002 Feb; 4(2):207-14. PubMed ID: 11880054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
    Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
    AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High thymic volume is associated with viral replication and immunologic impairment only early after HAART interruption in chronic HIV infection.
    Vallejo A; Valladares A; De Felipe B; Vivancos J; Gutierrez S; Soriano-Sarabia N; Ruiz-Mateos E; Lissen E; Leal M
    Viral Immunol; 2005; 18(4):740-6. PubMed ID: 16359240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
    Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
    AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference for CD4-guided versus continuous HARRT in Thailand.
    Ananworanich J; Pumpradit W; Apateerapong W; Siangphoe U; Saenawat S; Phanuphak P; Hirschel B
    AIDS Care; 2008 Mar; 20(3):327-30. PubMed ID: 18351480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
    Sued O; Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Claramonte X; Plana M; Tuset M; Pumarola T; Gallart T; Gatell JM; Miró JM
    PLoS One; 2015; 10(7):e0131651. PubMed ID: 26186440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline HIV RNA and the when to start question: time to stop asking this question?
    Mussini C
    AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
    [No Abstract]   [Full Text] [Related]  

  • 18. When to start, when to STI (or, groping for the golden moment).
    Mascolini M
    IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions.
    Hawley-Foss N; Mbisa G; Lum JJ; Pilon AA; Angel JB; Garber G; Badley AD
    Clin Infect Dis; 2001 Aug; 33(3):344-8. PubMed ID: 11438900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.